Do analysts recommend ACTU or XCUR?

Actuate Therapeutics currently has a consensus price target of $17.50, suggesting a potential upside of 1,196.30%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ACTU or XCUR more profitable?

Exicure's return on equity of -179.41% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Exicure N/A -179.41% -64.37%

Do analysts prefer ELUT or XCUR?

Elutia currently has a consensus target price of $6.00, indicating a potential upside of 531.58%. Given Elutia's stronger consensus rating and higher probable upside, analysts clearly believe Elutia is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, ELUT or XCUR?

Elutia has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elutia $12.46M 3.26 $53.38M $0.86 1.10 Exicure $500K 24.10 -$4.95M -$1.55 N/A

Is ELUT or XCUR more profitable?

Elutia has a net margin of 312.09% compared to Exicure's net margin of 0.00%. Elutia's return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Elutia 312.09% N/A -53.97% Exicure N/A -179.41% -64.37%

Do analysts prefer APLM or XCUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, APLM or XCUR?

Exicure has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 4.77 -$10.94M N/A N/A Exicure $500K 24.10 -$4.95M -$1.55 N/A

Is APLM or XCUR more profitable?

Apollomics' return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Exicure N/A -179.41% -64.37%

Do analysts prefer XCUR or LTRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is XCUR or LTRN more profitable?

Exicure's return on equity of -179.41% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Lantern Pharma N/A -198.34% -129.08%

Do analysts rate GRCE or XCUR?

Grace Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 144.40%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Grace Therapeutics is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRCE or XCUR more profitable?

Grace Therapeutics' return on equity of -14.45% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -14.45% -13.58% Exicure N/A -179.41% -64.37%

Exicure (XCUR) Competitors

$1.89 +0.00 (+0.11%)

As of 02:17 PM Eastern

Compare

XCUR vs. ACTU, ELUT, APLM, LTRN, and GRCE

Should you buy Exicure stock or one of its competitors? MarketBeat compares Exicure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exicure include Actuate Therapeutics (ACTU), Elutia (ELUT), Apollomics (APLM), Lantern Pharma (LTRN), and Grace Therapeutics (GRCE). These companies are all part of the "pharmaceutical products" industry.

How does Exicure compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

42.8% of Exicure shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by insiders. Comparatively, 52.8% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Actuate Therapeutics has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Exicure has a beta of 3.61, indicating that its share price is 261% more volatile than the broader market.

In the previous week, Exicure's average media sentiment score of 0.59 beat Actuate Therapeutics' score of 0.00 indicating that Exicure is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Neutral
Exicure	Positive

Actuate Therapeutics currently has a consensus price target of $17.50, suggesting a potential upside of 1,196.30%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Exicure has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Exicure	$500K	24.10	-$4.95M	-$1.55	N/A

Exicure's return on equity of -179.41% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Exicure	N/A	-179.41%	-64.37%

Summary

Exicure beats Actuate Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Exicure compare to Elutia?

Elutia (NASDAQ:ELUT) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Elutia has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Exicure has a beta of 3.61, meaning that its share price is 261% more volatile than the broader market.

In the previous week, Elutia had 3 more articles in the media than Exicure. MarketBeat recorded 3 mentions for Elutia and 0 mentions for Exicure. Exicure's average media sentiment score of 0.59 beat Elutia's score of 0.33 indicating that Exicure is being referred to more favorably in the news media.

Company	Overall Sentiment
Elutia	Neutral
Exicure	Positive

Elutia has a net margin of 312.09% compared to Exicure's net margin of 0.00%. Elutia's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
Exicure	N/A	-179.41%	-64.37%

74.0% of Elutia shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 17.8% of Elutia shares are owned by insiders. Comparatively, 52.8% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Elutia currently has a consensus target price of $6.00, indicating a potential upside of 531.58%. Given Elutia's stronger consensus rating and higher probable upside, analysts clearly believe Elutia is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Elutia has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.46M	3.26	$53.38M	$0.86	1.10
Exicure	$500K	24.10	-$4.95M	-$1.55	N/A

Summary

Elutia beats Exicure on 12 of the 16 factors compared between the two stocks.

How does Exicure compare to Apollomics?

Apollomics (NASDAQ:APLM) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

In the previous week, Apollomics had 2 more articles in the media than Exicure. MarketBeat recorded 2 mentions for Apollomics and 0 mentions for Exicure. Exicure's average media sentiment score of 0.59 beat Apollomics' score of 0.20 indicating that Exicure is being referred to more favorably in the news media.

Company	Overall Sentiment
Apollomics	Neutral
Exicure	Positive

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Apollomics' return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Exicure	N/A	-179.41%	-64.37%

Apollomics has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Exicure has a beta of 3.61, meaning that its share price is 261% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Exicure has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	4.77	-$10.94M	N/A	N/A
Exicure	$500K	24.10	-$4.95M	-$1.55	N/A

Summary

Exicure beats Apollomics on 6 of the 10 factors compared between the two stocks.

How does Exicure compare to Lantern Pharma?

Exicure (NASDAQ:XCUR) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

In the previous week, Exicure's average media sentiment score of 0.59 beat Lantern Pharma's score of 0.00 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
Lantern Pharma	Neutral

42.8% of Exicure shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 8.5% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Exicure's return on equity of -179.41% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Lantern Pharma	N/A	-198.34%	-129.08%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Exicure has a beta of 3.61, suggesting that its share price is 261% more volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market.

Exicure has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	24.10	-$4.95M	-$1.55	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

Summary

Exicure beats Lantern Pharma on 9 of the 10 factors compared between the two stocks.

How does Exicure compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

In the previous week, Exicure's average media sentiment score of 0.59 beat Grace Therapeutics' score of 0.00 indicating that Exicure is being referred to more favorably in the news media.

Company	Overall Sentiment
Grace Therapeutics	Neutral
Exicure	Positive

Grace Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 144.40%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Grace Therapeutics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Grace Therapeutics' return on equity of -14.45% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-14.45%	-13.58%
Exicure	N/A	-179.41%	-64.37%

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by insiders. Comparatively, 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Grace Therapeutics has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Exicure has a beta of 3.61, meaning that its share price is 261% more volatile than the broader market.

Exicure has higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A
Exicure	$500K	24.10	-$4.95M	-$1.55	N/A

Summary

Exicure beats Grace Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Exicure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XCUR vs. The Competition

Export

Metric	Exicure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.09M	$3.65B	$6.80B	$12.44B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-1.22	20.66	27.00	24.19
Price / Sales	24.10	322.67	518.66	94.29
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	3.05	8.17	10.68	6.26
Net Income	-$4.95M	$23.81M	$3.59B	$331.52M
7 Day Performance	10.00%	-1.53%	-0.19%	-1.19%
1 Month Performance	-18.10%	2.21%	1.93%	-1.35%
1 Year Performance	-78.65%	44.90%	25.24%	18.74%

Exicure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XCUR Exicure	0.9 of 5 stars	$1.89 +0.1%	N/A	-76.2%	$12.09M	$500K	N/A	50	Gap Down
ACTU Actuate Therapeutics	2.3563 of 5 stars	$1.72 -0.6%	$17.50 +917.4%	-75.7%	$41.16M	N/A	N/A	10
ELUT Elutia	3.0026 of 5 stars	$0.96 +5.3%	$6.00 +525.1%	-56.1%	$41.07M	$12.46M	1.12	180
APLM Apollomics	0.7844 of 5 stars	$18.43 +17.4%	N/A	+203.7%	$40.55M	$8.50M	N/A	45	High Trading Volume
LTRN Lantern Pharma	0.8589 of 5 stars	$3.10 +1.0%	N/A	-26.1%	$39.56M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XCUR) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exicure (XCUR) Competitors

XCUR vs. ACTU, ELUT, APLM, LTRN, and GRCE

How does Exicure compare to Actuate Therapeutics?

Summary

How does Exicure compare to Elutia?

Summary

How does Exicure compare to Apollomics?

Summary

How does Exicure compare to Lantern Pharma?

Summary

How does Exicure compare to Grace Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exicure (XCUR) Competitors

XCUR vs. ACTU, ELUT, APLM, LTRN, and GRCE

How does Exicure compare to Actuate Therapeutics?

Do institutionals and insiders hold more shares of ACTU or XCUR?

Which has more risk and volatility, ACTU or XCUR?

Does the media favor ACTU or XCUR?

Do analysts recommend ACTU or XCUR?

Which has higher earnings & valuation, ACTU or XCUR?

Is ACTU or XCUR more profitable?

Summary

How does Exicure compare to Elutia?

Which has more risk and volatility, ELUT or XCUR?

Does the media prefer ELUT or XCUR?

Is ELUT or XCUR more profitable?

Do institutionals and insiders believe in ELUT or XCUR?

Do analysts prefer ELUT or XCUR?

Which has preferable earnings & valuation, ELUT or XCUR?

Summary

How does Exicure compare to Apollomics?

Does the media prefer APLM or XCUR?

Do insiders & institutionals believe in APLM or XCUR?

Is APLM or XCUR more profitable?

Which has more volatility & risk, APLM or XCUR?

Do analysts prefer APLM or XCUR?

Which has better earnings and valuation, APLM or XCUR?

Summary

How does Exicure compare to Lantern Pharma?

Does the media refer more to XCUR or LTRN?

Do insiders & institutionals believe in XCUR or LTRN?

Is XCUR or LTRN more profitable?

Do analysts prefer XCUR or LTRN?

Which has more risk & volatility, XCUR or LTRN?

Which has better earnings & valuation, XCUR or LTRN?

Summary

How does Exicure compare to Grace Therapeutics?

Does the media prefer GRCE or XCUR?

Do analysts rate GRCE or XCUR?

Is GRCE or XCUR more profitable?

Do institutionals & insiders have more ownership in GRCE or XCUR?

Which has more risk and volatility, GRCE or XCUR?

Which has higher valuation and earnings, GRCE or XCUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools